Used in the development of therapies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) to lower low-density lipoprotein (LDL) cholesterol levels. It serves as a reference standard in bioassays to evaluate the potency and efficacy of PCSK9 inhibitors. Employed in research and quality control during the manufacturing of biosimilars and novel anti-PCSK9 monoclonal antibodies. Helps in characterizing binding affinity and neutralizing activity against PCSK9, supporting drug discovery and regulatory approval processes.